Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEA-specific cytotoxic T lymphocytes
- Development stage
- Phase 1
- Lead developer
- Changzhou First People's Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
CEA-specific cytotoxic T lymphocytes (CTLs) are an autologous cellular immunotherapy developed by The First People's Hospital of Changzhou for the treatment of stage IV gastric cancer. The production process involves isolating a patient's peripheral blood mononuclear cells, differentiating them into dendritic cells (DCs), and transducing them with a recombinant adeno-associated virus (rAAV) carrying the carcinoembryonic antigen (CEA) gene. These CEA-expressing DCs are then used to prime and expand autologous T cells ex vivo, generating a population of CTLs specifically programmed to recognize and eliminate CEA-positive tumor cells. This approach leverages the high expression of CEA in gastric cancers to provide a targeted immune response against tumor cells while minimizing off-target effects.
- Other names
- CEA-specific CTLsrAAV-CEA-DC-induced CTLsrAAV-CEA infected dendritic cell-induced cytotoxic T lymphocytes
02
Targets
Carcinoembryonic antigen-related cell adhesion molecule 5 peptide-HLA class I complex
Beyond the preview
Go deeper on CEA-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEA-specific cytotoxic T lymphocytes.